Scholars Central

Conference abstractPublished 21 Nov 2016

Gankyrin: A novel gene that promotes tamoxifen resistance in breast cancer patients

Authors: Khadijeh Jamialahmadi, Rosa Jahangiri, Masoumeh Gharib, Amirnader Emami Razavi

Mashhad University of Medical Sciences, Iran Tehran University of Medical Sciences, Iran

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Breast cancer is the most frequent malignancy in women worldwide. Oestrogen receptor Ã?± (ERÃ?±) antagonists like tamoxifen are used in endocrine therapies for ERÃ?±-positive (ERÃ?±+) breast cancer patients. Unfortunately, the clinical benefit is limited due to intrinsic and acquired drug resistance. Gankyrin (P28GANK) is a newly defined oncoprotein which was reported to confer a multidrug resistant phenotype in some cancer cells. Gankyrin also functions as a dual-negative regulator of the two most important tumor suppressor pathways: (I) INK4-CDK-pRb, and (II) ARF-MDM2-p53. In the present study, the levels of protein expression and mRNA transcripts were determined using immunohistochemical analysis and Real-Time quantitative PCR in 72 matched formalinfixed paraffin-embedded and fresh frozen breast cancer tissues (36 tamoxifen resistant and 36 tamoxifen sensitive). Overexpression of P28GANK was present in about 56% of the tamoxifen sensitive breast cancer patients and more frequently (91%) in tamoxifenrefractory tumors. P28GANK gene was also found to be overexpressed at the protein level in tamoxifen resistance patients compared to tamoxifen sensitive samples (p=0.045). These results for the first time suggest that Gankyrin plays a role in tamoxifen-resistant breast cancer, and the inhibition of this oncoprotein may be a potential target for re-sensitizing the resistant breast cancer patients to tamoxifen-treatment in endocrine-resistant breast cancer patients

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Khadijeh Jamialahmadi”
  • BylineArticles whose byline prints “Rosa Jahangiri”
  • BylineArticles whose byline prints “Masoumeh Gharib”
  • BylineArticles whose byline prints “Amirnader Emami Razavi”